International Journal of Hematology

, Volume 91, Issue 2, pp 201–208 | Cite as

Guidelines for safety management of granulocyte transfusion in Japan

  • Akimichi OhsakaEmail author
  • Atsushi Kikuta
  • Hitoshi Ohto
  • Akira Ohara
  • Akaru Ishida
  • Koji Osada
  • Tetsunori Tasaki
  • Akira Kamitamari
  • Asayuki Iwai
  • Shunro Kai
  • Taira Maekawa
  • Yasutaka Hoshi


Granulocyte transfusion (GTX) has recently been revived by the ability to stimulate granulocyte donors with granulocyte colony-stimulating factor (G-CSF), resulting in a greatly increased number of cells that can be collected. However, there is a paucity of guidelines for assessing the appropriateness and safety management of GTX. The objective of this study was to establish guidelines for the safety management of GTX appropriate for the clinical situation in Japan. The Japan Society of Transfusion Medicine and Cell Therapy, Granulocyte Transfusion Task Force issued the first version of guidelines for GTX considering the safety management of both granulocyte donors and patients who receive GTX therapy. The current guidelines cover issues concerning: (1) the appropriateness of medical institutions, (2) management of granulocyte donors, (3) quality assurance of granulocyte concentrates, (4) administration of granulocyte concentrates, (5) evaluation of the effectiveness of GTX therapy, and (6) complications of GTX therapy. The simple ‘bag separation method’ without apheresis may be recommended for granulocyte collection in pediatric patients. The first version of guidelines for GTX therapy has been established, which may be appropriate for the clinical situation in Japan. Care should be taken to perform the safety management of both granulocyte donors and patients who receive GTX therapy.


Granulocyte transfusion Guidelines Granulocyte colony-stimulating factor Safety management 


Conflict of interest statement

The authors declare no conflicts of interest.


  1. 1.
    Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol. 2003;30(4 Suppl 13):3–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–40.PubMedGoogle Scholar
  3. 3.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Neuburger S, Maschmeyer G. Update on management of infections in cancer and stem cell transplant patients. Ann Hematol. 2006;85:345–56.CrossRefPubMedGoogle Scholar
  5. 5.
    Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol. 2007;14:3–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Ohsaka A, Kitagawa S, Sakamoto S, Miura Y, Takanashi N, Takaku F, et al. In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood. 1989;74:2743–8.PubMedGoogle Scholar
  7. 7.
    Yuo A, Kitagawa S, Ohsaka A, Ohta M, Miyazono K, Okabe T, et al. Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood. 1989;74:2144–9.PubMedGoogle Scholar
  8. 8.
    Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111:1767–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007;44:15–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion. 2000;40:642–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion. 2001;41:1037–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–9.PubMedGoogle Scholar
  13. 13.
    Atallah E, Schiffer CA. Granulocyte transfusion. Curr Opin Hematol. 2006;13:45–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903–8.PubMedGoogle Scholar
  15. 15.
    Volk EE, Domen RE, Smith ML. An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med. 1999;123:508–13.PubMedGoogle Scholar
  16. 16.
    Bux J, Cassens U, Dielschneider T, Duchscherer M, Edel E, Eichler H, et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang. 2003;85:322–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Kikuta A, Ohto H, Nemoto K, Mochizuki K, Sano H, Ito M, et al. Therapeutic transfusions of granulocytes collected by simple bag method for children with cancer and neutropenic infections: results of a single-centre pilot study. Vox Sang. 2006;91:70–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Mochizuki K, Kikuta A, Ohto H, Nemoto K, Ito M, Sano H, et al. Extended storage of granulocyte concentrates mobilized by G-CSF with/without dexamethasone and collected by bag separation method. Transfus Med. 2007;17:296–303.CrossRefPubMedGoogle Scholar
  19. 19.
    Adkins D, Ali S, Despotis G, Dynis M, Goodnough LT. Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte-colony-stimulating factor. Transfusion. 1998;38:557–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Rühl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev. 2009;23:62–71.CrossRefPubMedGoogle Scholar
  21. 21.
    Brecher ME, editor. AABB technical manual, 15th ed. Bethesda: American Association of Blood Banks; 2005.Google Scholar
  22. 22.
    Ohto H, Yasuda H, Noguchi M, Abe R. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion. 1992;32:691–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Asai T, Inaba S, Ohto H, Osada K, Suzuki G, Takahashi K, et al. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan. Transfus Med. 2000;10:315–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Nemoto K, Kikuta A, Ohto H, Sano H, Itoh M, Suzuki H. Collection by a simple bag method and the function of granulocytes in granulocyte transfusion. Int J Hematol. 2006;84:43–7.CrossRefPubMedGoogle Scholar
  25. 25.
    British Committee for Standards in Haematology. Transfusion guidelines for neonates and older children. Br J Haematol. 2004;124:433–53.CrossRefGoogle Scholar
  26. 26.
    Liles WC, Klebanoff SJ. Regulation of apoptosis in neutrophils—Fas track to death? J Immunol. 1995;155:3289–91.PubMedGoogle Scholar
  27. 27.
    Drewniak A, Boelens JJ, Vrielink H, Tool AT, Bruin MC, van den Heuvel-Eibrink M, et al. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica. 2008;93:1058–67.CrossRefPubMedGoogle Scholar
  28. 28.
    D’Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. 2008;22:280–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40:185–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48:1495–501.CrossRefPubMedGoogle Scholar
  31. 31.
    Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion. 2009;49:513–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95:2269–74.PubMedGoogle Scholar
  33. 33.
    Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion. 2001;41:1464–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Burch JW, Mair DC, Meny GM, Moroff G, Ching SS, Naidoff MA, et al. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion. 2005;45:1701–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol. 2004;127:501–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Schiffer CA, Aisner J, Daly PA, Schimpff SC, Wiernik PH. Alloimmunization following prophylactic granulocyte transfusion. Blood. 1979;54:766–74.PubMedGoogle Scholar
  37. 37.
    Dutcher JP, Kendall J, Norris D, Schiffer C, Aisner J, Wiernik PH. Granulocyte transfusion therapy and amphotericin B: adverse reactions? Am J Hematol. 1989;31:102–8.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Akimichi Ohsaka
    • 1
    Email author
  • Atsushi Kikuta
    • 2
  • Hitoshi Ohto
    • 3
  • Akira Ohara
    • 4
  • Akaru Ishida
    • 5
  • Koji Osada
    • 6
  • Tetsunori Tasaki
    • 6
  • Akira Kamitamari
    • 7
  • Asayuki Iwai
    • 8
  • Shunro Kai
    • 9
  • Taira Maekawa
    • 10
  • Yasutaka Hoshi
    • 6
  1. 1.Department of Transfusion Medicine and Stem Cell RegulationJuntendo University School of MedicineTokyoJapan
  2. 2.Department of PediatricsFukushima Medical UniversityFukushimaJapan
  3. 3.Division of Blood Transfusion and Transplantation ImmunologyFukushima Medical UniversityFukushimaJapan
  4. 4.Division of Transfusion MedicineToho University Omori Medical CenterTokyoJapan
  5. 5.Department of Internal MedicineTachikawa Hospital, Federation of National Public Service Personnel Mutual Aid AssociationsTokyoJapan
  6. 6.Blood Transfusion ServiceTokyo Jikei University HospitalTokyoJapan
  7. 7.Department of PediatricsSasebo City General HospitalNagasakiJapan
  8. 8.Department of PediatricsIwakuni Children’s HospitalKochiJapan
  9. 9.Department of Transfusion MedicineHyogo College of MedicineNishinomiyaJapan
  10. 10.Department of Transfusion Medicine and Cell TherapyKyoto University HospitalKyotoJapan

Personalised recommendations